Novartis names ex-BMS CEO Caforio as chair amid strong Q1
Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive
Shakeup at BenevolentAI continues with job, programme cuts
BenevolentAI is embarking on another round of job losses, closing its US office, and shelving its software-as-a-service business to extend its cash reserves into the third
FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt
After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product.
EU approves Pfizer antibiotic for superbug infections
Pfizer’s Emblaveo has been approved in the EU with a first-in-class indication in multidrug-resistant (MDR) infections.
BMS preps for CAR-T growth with $380m Cellares deal
Bristol-Myers Squibb has shored up manufacturing of its CAR-T therapies, tapping into capacity at contract manufacturer Cellares that will be used to supply patients in th
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
FT US PHARMA AND BIOTECH SUMMIT
2024 is a pivotal year for the US healthcare sector.
The PM Society – Giving Back
The PM Society is a not-for-profit organisation with 40 years of Giving Back.
5th Optimizing Hybrid Clinical Trials Summit
The 5th Optimizing Hybrid Clinical Trials Summit (September 11-12, 2024 | Boston, MA) is uniting stakeholders in Clinical Operations, Innovation, Procurement and Digital Health and
2nd RNA Assay Development Screening Summit
This August, the 2nd RNA Assay Development & Screening Summit returns to Boston as the first and only industry dedicated event on developing sensitive, and reproducible assay and screening meth
3rd HF Drug Discovery & Development Summit
The Industry’s Only Definitive Forum for Preclinical Heart Failure Drug Development